Clinical Study To find The Effect Of Triphaladi Arka In Neonatal Hyperbilirubinemia

Randomized Controlled Clinical Study To Evaluate The Effect Of Triphaladi Arka In Neonatal Hyperbilirubinemia - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/081454

Enrollment

Registered

2025-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P599- Neonatal jaundice, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Healthy neonates of either gender, irrespective of caste and creed extracted through LSCS. Term neonates with body weight between 2500 to 3500 grams. Neonates, whose parents are willing to give consent for the trial.

Exclusion criteria

Exclusion criteria: Newborn with birth asphyxia or with APGAR score less than 7 Newborn with congenital anomalies Newborns with any medical or surgical illness

Design outcomes

Primary

Measure	Time frame
Samples Of Blood Will Be Collected In Two Groups Of New Borns First Group Will Be Intervened With Triphaladi Arka Along With Routine New Born Care And Second Group Will Be Control Group Who Will Be Given Only New Born CareTimepoint: Samples Of Blood Will Be Collected In Two Groups Of New Borns New Borns Will be Assessed For Serum Bilirubin And Kramers Rule At Interval Of Birth Day , Second Day, Fourth Day And Sixth Day	—

Measure

Time frame

Samples Of Blood Will Be Collected In Two Groups Of New Borns First Group Will Be Intervened With Triphaladi Arka Along With Routine New Born Care And Second Group Will Be Control Group Who Will Be Given Only New Born CareTimepoint: Samples Of Blood Will Be Collected In Two Groups Of New Borns New Borns Will be Assessed For Serum Bilirubin And Kramers Rule At Interval Of Birth Day , Second Day, Fourth Day And Sixth Day

—

Secondary

Measure	Time frame
To Evaluate The Effect Of Triphaladi Arka In Neonatal hyperbilirubinemiaTimepoint: Assessment Of Serum Bilirubin And Kramers Rule At Intervals Of Birth Day, Second Day , Fourth Day And Sixth Day	—

Countries

India

Contacts

Public ContactDr Nayan Kumar S

Rajiv Gandhi University of Health Sciences, Banglore

drnayankumar@sdmcahhassan.org8197589426

Outcome results